1. Introduction
Ocular toxoplasmosis (OT) is a major cause of posterior uveitis worldwide but its incidence and prevalence are difficult to establish precisely. In 1993, a survey in a French Hospital Service of Ophthalmology showed that OT was seen in less than 1 per thousand outpatients [1]. In a study performed in Germany, toxoplasmosis accounted for 4.2 % of all cases of uveitis at a referral centre [2]. Around 5000 people develop symptomatic OT each year in the United States [3]. OT is a complication of both acute acquired and reactivated congenital in immunocompetent but particularly in immunocompromissed individuals and its severity can be influenced by variation in parasite isolates, parasitic load, route of infection and host-related factors such as immune function, age and pregnancy. Diagnosis is usually based on ophthalmological examination and is confirmed by the response to specific treatment, but also by biological assays including local antibody production, PCR and western blot. All these points will be detailed below.
2. A complication of acquired and congenital infections
Classically, retinochoroiditis secondary to acquired toxoplasmosis was considered an exceptional event in immunocompetent individuals, and was usually defined as a periodic reactivation of latent cysts associated with undiagnosed congenital infections. But recent data, based on ophthalmological examination, seem to establish that acquired infection might be responsible for most cases. This fact was particularly demonstrated by outbreaks reported in Canada, Brazil and India. In Canada, amongst 100 individuals infected during a water-borne outbreak, 19 had OT [4]. In southern Brazil 17.7% of 1,042 individuals examined had OT with lesions in 0.9% of 1- to 8-year-olds and in 21.3% of all individuals older than 13, suggesting that in this population, the disease was a sequel of postnatal rather than congenital infection [5]. In India, Balasundaram et al. [6] described ocular involvement due to toxoplasmosis in 248 patients who had active retinochoroiditis and toxoplasmic serology suggesting recently acquired disease. Delair et al. [7] analysed 425 cases of OT, 100 (23.5%) were acquired, 62 (14.6%) were congenital, and 263 (61.9%) were of unknown origin. At the time of the study, the mean age of the patients with congenital OT was 9.1 +/- 8.8 years, and 21.7 +/- 12.6 years in the patients with the acquired disease (p < 0.001). Bilateral OT was only found in 4% of acquired cases and in 43.5% of congenital cases (p < 0.001) and in acquired infections, visual acuity was significantly less impaired than in congenital infections. In the United Kingdom, 50% of OT in children was acquired after birth and no clear clinical distinction could be made between acquired and congenital toxoplasmosis (CT) [8]. However, other authors have identified clinical presentations specific to each group. Montoya et al. (1996) observed that patients with post-natal acquired toxoplasmic retinochoroiditis had mostly unilateral lesions without old scars or involvement of the macula [9]. In case of congenital origin, the risk of ocular disease depends on the trimester of pregnancy when infection occurred, and on whether or not treatment was administered to the mother during pregnancy. In one study, a period exceeding 8 weeks between maternal infection and the beginning of treatment, female gender, and especially cerebral calcifications were risk factors for retinochoroiditis [10]. No significant association was found in other cohort studies between gestational age at maternal infection, prenatal treatment and the risk of developing OT [11, 12].
3. Occurrence depends on host genetic background and immune status
In mice, the severity of ocular damage is linked to many factors related to either host immunity or the parasite, such as inoculum size, infective stage (oocysts versus cysts), route of infection and the genotype of the infecting strain. However, these data are not well documented in humans. The acquired immune deficiency syndrome (AIDS) epidemic has dramatically reminded that effective host immunity was essential to limit the severity of ocular lesions. AIDS patients without highly active antiretroviral therapy can develop extensive and recurring lesions [13]. Similar lesions may also be encountered during the use of immunosuppressive drugs [9, 14]. Many studies have focused on elderly patients [15-17]. These patients can have large and multiple ocular lesions with severe vitritis and prolonged disease, in some instances similar to lesions encountered in immunocompromissed individuals, although they are otherwise healthy. Indeed, both cellular and humoral immune responses are modified with advancing age and probably contribute to the higher severity of OT in older patients [16]. A cross-sectional household study involving 499 individuals was undertaken in Minas Gerais state of Brazil, where infection with
4. Specific parasitic genotypes could be involved
Currently, it is assumed that the population of
5. Immune privileged status and cytokine responses are key factors in toxoplasmic retinochoroiditis
The pathogenesis of OT is directly linked to the anatomical characteristics of the eye resulting in an immune privileged status. The presence of the hemato-retinal barrier and the absence of lymphatic vessels limits the passage of inflammatory cells and lymphocytes and of antibodies and complement components [34]. In addition, the ocular characteristics of the distribution and the functions of antigen presenting cells are also of importance. For example, corneal epithelium is deprived of Langerhans cells and the dendritic cells of the ciliary epithelium are not activated by GM-CSF and do not stimulate T lymphocytes [35, 36]. There is a low expression of classical MHC class IA molecules which reduce the lytic activity of CD8+ lymphocytes usually stimulated by the MHC I molecules. MHC II molecules are not expressed in the eye, which limits CD4+ lymphocyte activation. Increased expression of surface molecules like CD46, CD55 and CD59 will also inhibit complement activation [37]. A local production of immunosuppressive cytokines, such as TGF-β, limits B and Th1 lymphocyte activation but activates Th2 lymphocytes [34, 38, 39]. Finally, retinal cells express surface molecules involved in apoptosis such as TNF- Related Apoptosis Inducing Ligand (TRAIL) and Fas ligand (FasL). FasL interacts with FasR (Fas receptor) carried by the inflammatory cells, inducing their apoptosis. This would control the entry of Fas-expressing lymphoid cells and limit the alteration of ocular cells by these cells [40, 41]. Whereas the mechanisms that underlie retinal damage in OT are yet not fully understood, the immune response might directly affect the pathogenesis of toxoplasmic retinochoroiditis and some cytokines have been shown to be fundamental to either control or block a protective response against
6. Diagnosis is based on clinical signs and some selected biological assays
The diagnosis is usually based on ophthalmological examination showing unilateral, whitish, fuzzy-edged, round, focal lesions surrounded by retinal edema (figure 2). Cells are found in the vitreous, particularly overlying the active lesion. In the area surrounding the active retinitis, one may see hemorrhage, as well as sheathing of the retinal blood vessels. Fluorescein angiography of the active lesion demonstrates early blockage with subsequent leakage of the lesion. Cells in the anterior chamber may also be noted and may appear to be either a granulomatous or non granulomatous uveitis. The discovery of healed pigmented

Figure 1.
T cells and cytokines involved in ocular toxoplasmosis and parasite destruction

Figure 2.
Eye fundus aspects of ocular toxoplasmosis. a: active lesion; b, d: scar; c: active lesion and scars (source A.P. Brézin and Anofel)
retinochoroidal scars facilitates the diagnosis [57, 58]. OT is also confirmed by a favorable clinical response to specific therapy. However, diagnosis and treatment can be delayed in patients with atypical lesions (unusual and complicated forms) or patients showing an inadequate response to antimicrobial therapy as particularly observed in elderly or immunocompromised patients [13, 17]. In such cases, rapid identification of the causative agent requires aqueous humor sampling by anterior chamber paracentesis [59]. Laboratory diagnosis is based on the comparison of antibody profiles in ocular fluid and serum samples in order to detect intraocular specific antibody synthesis, based on the Goldmann-Witmer coefficient (GWC) or on the observation of qualitative differences between eye fluid and serum by immunoblotting (IB) [60]. The GWC is based on the comparison of the levels of specific antibodies to total immunoglobulin in both aqueous humor and serum. Recent studies have shown the usefulness of PCR applied to aqueous humor, in combination with serologic tests, for the diagnosis of OT [61-68]. However, although this combined approach improves diagnostic sensitivity, the volume of the ocular fluid sample may not be adequate for PCR, IB, and GWC. We showed [68] that a combination of all three methods had a 85% sensitivity and a 93% specificity for the diagnosis of atypical or extensive toxoplasmic retinochoroiditis. The sensitivity of GWC alone for atypical uveitis (based mainly on aqueous humor samples) ranges from 39% to 93% [60, 63, 65, 67, 69-71]. Discrepancies could be explained by differences in (i) the interval between symptom onset and paracentesis, (ii) the characteristics of the uveitis (typical or atypical), (iii) underlying immunological status, and (iv), the chosen GWC positivity threshold, which ranges from 2 to 8 in the literature. The specificity of the GWC is usually high if the retinal barrier has not been impaired. IB on aqueous humor has sensitivities ranging from 50 to 81% for the diagnosis of atypical [60, 65] and typical [66, 68, 69] OT. Apparently the sensitivity of IB increases with the length of the interval between onset of symptoms and paracentesis. The sensitivity of real-time PCR ranges from 36 % to 55% [63, 67, 68]. The sensitivity was higher with a real-time PCR assay targeting the

Figure 3.
Algorithm for the biological diagnosis of ocular toxoplasmosis (in severely immunosuppressed patients a negative serology does not exclude OT which can be then confirmed by PCR)
7. Efficient treatments are available but there is no real mean of prevention
There is no real consensus on the treatment of retinochoroiditis [72-75]. Some experts will treat only patients in which the lesions are near the macula or the optic nerve and when there is an important hyalitis with an impairment of the optical acuity. The non-treated patient will be regularly checked. Other experts will treat all the lesions whatever their localizations and this is now possible because the recommended association pyrimethamine/azythromycine is better tolerated and has a better compliance than pyrimethamine associated to sulfadiazine [76, 77]. Corticosteroids (prednisone at 0.5 to 1mg/kg/d) are constantly administered for several weeks, except for immunocompromised patients [73, 78]. Pyrimethamine in adults is used at 100mg/d for several days then decreased at 50mg/d. It should be associated with sulfadiazine at 75mg/kg/d divided in 4 doses or better with azythromycine 250 mg/d. The total length of the treatment will be of 3 to 6 weeks, sometimes more, depending on the initial size of the lesion. In patients intolerant to treatment, clindamycine at 450-600 mg/d should be associated [79]. The treatment of congenital retinochoroiditis in newborns is based on sulfadiazine (50mg/kg/d in 2 doses) associated with pyrimethamine at 1mg/kg/d for 6 to 12 months. Fifteen mg folinic acid is given every 3 days. The prophylaxis of congenitally acquired OT is based on national programs of prevention of CT (e.g. France, Austria) but their efficiency is discussed [80-82] and depends on the local epidemiology and virulence of strains [83]. Peyron et al. [84] stated that ”treating CT has little effect on the quality of life and visual function of the affected individuals”. However, Kieffer et al. [10] showed that a period exceeding 8 weeks between maternal infection and the beginning of treatment was a risk factor for retinochoroiditis; therefore emphasizing the need to prevent and treat CT. Evidence for the effectiveness of prenatal or postnatal treatment for CT is still needed. Randomised controlled trials and cohort studies are in progress to provide information on prognosis, especially disability [85]. There is no radical prevention of acquired toxoplasmosis besides hygienic rules in preparing meals. Eating well done or deeply frozen meat should be particularly recommended in regions where highly pathogenic isolates are prevalent. In HIV patients, drug prevention of toxoplasmosis has been successfully used for years and is now less needed since the use of efficient HAART.
8. Conclusions
Acquired or CT can be complicated by OT. The diagnosis relies on clinical aspects, responses to specific treatment and results of biological assays. The incidence and the prevalence of this complication are both difficult to establish precisely and depend on the parasite prevalence in the general population, and are affected by different factors such as type of exposure to the parasite, genetic background of the different parasites and the host, and the type of immune response elicited by the parasite. Prevention of CT (though still discussed), and a rapid specific treatment of acquired cases could be the key measures to avoid severe visual impairment but evaluation of these procedures is urgently needed.
AcknowledgementParts of this chapter were already published in Factors of occurrence of ocular toxoplasmosis. A review. Talabani H, Mergey T, Yera H, Delair E, Brézin AP, Langsley G, Dupouy-Camet J. Parasite. 2010 Sep;17(3):177-82. This chapter is published with the help of ADERMEPT.
References
- 1.
Dupouy-Camet J, Lahmi T., Vidal-Trecan G, Ancelle T, Mondon H. Prévalence des choriorétinites toxoplasmiques chez 4019 consultants d’un service d’ophtalmologie. Bulletin Epidémiologique Hebdomadaire 1995; 95(2):7 http://archives.invs.sante.fr/beh/1995/02/beh_02_1995.pdf - 2.
36 127 36 Jakob E, Reuland MS, Mackensen F, Harsch N, Fleckenstein M, Lorenz HM, Max R, Becker MD. Uveitis subtypes in a german interdisciplinary uveitis center-analysis of 1916 patients. J Rheumatol 2009; 36: 127-36 - 3.
Jones JL, Holland GN. Annual burden of ocular toxoplasmosis in the US. Am J Trop Med Hyg2010 82 464 5 - 4.
Outbreak of toxoplasmosis associated with municipal drinking water. LancetBowie W. R. AS King Werker. D. H. Isaac-Renton J. L. Bell A. Eng S. B. Marion S. A. 1997 350 173 7 - 5.
An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J OphthalmolGlasner P. D. Silveira C. Kruszon-Moran D. Martins M. C. Burnier Júnior. M. Silveira S. ME Camargo Nussenblatt. R. B. Kaslow R. A. Belfort Júnior. R. 1992 114 136 44 - 6.
Outbreak of acquired ocular toxoplasmosis involving 248 patients. Arch OphthalmolBalasundaram M. B. Andavar R. Palaniswamy M. Venkatapathy N. 2010 128 28 32 - 7.
Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J OphthalmolDelair E. Monnet D. Grabar S. Dupouy-Camet J. Yera H. Brezin A. P. 2008 146 851 855 - 8.
Stanford MR, Tan HK, Gilbert RE. Toxoplasmic retinochoroiditis presenting in childhood: clinical findings in a UK survey. Br J Ophthalmol2006 90 1464 7 - 9.
Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis1996 23 277 82 - 10.
Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis. Pediatr Infect Dis JKieffer F. Wallon M. Garcia P. Thulliez P. Peyron F. Franck J. 2008 27 27 32 - 11.
Prognostic factors for the long-term development of ocular lesions in 327 children with congenital toxoplasmosis. Epidemiol InfectBinquet C. Wallon M. Quantin C. Kodjikian L. Garweg J. Fleury J. Peyron F. Abrahamowicz M. 2003 131 1157 68 - 12.
Predictors of retinochoroiditis in children with congenital toxoplasmosis: European, prospective cohort study. PediatricsFreeman K. Tan H. K. Prusa A. Petersen E. Buffolano W. Malm G. Cortina-Borja M. Gilbert R. European Multicentre. Study on. Congenital Toxoplasmosis. 2008 121 1215 22 - 13.
Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J OphthalmolHolland G. N. Engstrom R. E. Jr Glasgow B. J. Berger B. B. Daniels S. A. Sidikaro Y. Harmon J. A. Fischer D. H. DS Boyer Rao. N. A. et al. 1988 106 653 67 - 14.
Intraocular anti-Toxoplasma gondii IgA antibody production in patients with ocular toxoplasmosis. Am J OphthalmolMJ Ronday Ongkosuwito. J. V. Rothova A. Kijlstra A. 1999 127 294 300 - 15.
Mem Inst Oswaldo CruzHolland G. Ocular toxoplasmosis. the influence. of patient. age 2009 104 351 7 - 16.
OphthalmologyJohnson M. W. Greven G. M. Jaffe G. J. Sudhalkar H. Vine A. K. Atypical severe. toxoplasmic retinochoroiditis. in elderly. patients 1997 104 48 57 - 17.
Ocular toxoplasmosis after the fifth decade. Am J OphthalmolLabalette P. Delhaes L. Margaron F. Fortier B. Rouland J. F. 2002 133 506 15 - 18.
J, Costa MI, Gazzinelli A, Vitor RW, Hermeto FM, Correa-Oliveira R, Gazzinelli RT. A multihousehold study reveals a positive correlation between age, severity of ocular toxoplasmosis, and levels of glycoinositolphospholipid-specific immunoglobulin A. J Infect DisPortela R. W. Bethony J. Costa M. I. Gazzinelli A. Vitor R. W. Hermeto F. M. Correa-Oliveira R. Gazzinelli R. T. A. multihousehold study. reveals a. positive correlation. between age. severity of. ocular toxoplasmosis. levels of. glycoinositolphospholipid-specific immunoglobulin. A. 2004 190 175 83 - 19.
OphthalmologyBosch-Driessen L. H. Berendscho T. T. Ongkosuwito J. V. Rothova A. Ocular toxoplasmosis. clinical features. prognosis of. 1. patients 2002 109 869 78 - 20.
Recurrence Characteristics in European Patients with Ocular Toxoplasmosis. Br J Ophthalmol.Garweg J. G. Scherrer J. N. Halberstadt M. 2008 92 1253 6 - 21.
Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol,Holland G. N. Crespi C. M. ten Dam-van. Loon N. Charonis A. C. Yu F. Bosch-Driessen L. H. Rothova A. 2008 145 1007 1013 - 22.
IFN-gamma-regulated Toxoplasma gondii distribution and load in the murine eye. Invest Ophthalmol Vis SciNorose K. Mun H. S. Aosai F. Chen M. Piao L. X. Kobayashi M. Iwakura Y. Yano A. I. F. 2003 44 4375 81 - 23.
HLA typing in congenital toxoplasmosis. Br J OphthalmolMeenken C. Rothova A. de Waal L. P. van der Horst A. R. Mesman B. J. Kijlstra A. H. L. 1995 79 494 7 - 24.
Host genetic and epigenetic factors in toxoplasmosis. Mem Inst Oswaldo CruzJamieson S. E. Cordell H. Petersen E. Mc Leod R. Gilbert R. E. Blackwell J. M. 2009 104 162 9 - 25.
Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends ParasitolSaeij J. Boyle J. P. Boothroyd J. C. 2005 21 476 81 - 26.
Globally diverse Toxoplasma gondii isolates comprise six major clades originating from a small number of distinct ancestral lineages. Proc Natl Acad Sci U S A.Su C. Khan A. Zhou P. Majumdar D. Ajzenberg D. Dardé M. L. Zhu X. Q. Ajioka J. W. BM Rosenthal Dubey. J. P. Sibley L. D. 2012 109 5844 9 - 27.
Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J Clin MicrobiolHowe D. K. Honoré S. Derouin F. Sibley L. D. 1997 35 1411 4 - 28.
Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect DisME Grigg Ganatra. J. Boothroyd J. C. Margolis T. P. 2001 184 633 9 - 29.
The genotype of Toxoplasma gondii strains causing ocular toxoplasmosis in humans in Brazil. Am J OphthalmolVallochi A. L. Muccioli C. Martins M. C. Silveira C. Belfort Jr R. Rizzo L. V. 2005 139 350 1 - 30.
Genetic divergence of Toxoplasma gondii strains associated with ocular toxoplasmosis, Brazil. Emerg Infect DisKhan A. Jordan C. Muccioli C. Vallochi A. L. Rizzo L. V. Belfort R. Jr Vitor R. W. Silveira C. Sibley L. D. 2006 12 942 9 - 31.
Incidence of acute symptomatic toxoplasma retinochoroiditis in south London according to country of birth. BMJGilbert R. E. Stanford M. R. Jackson H. Holliman R. E. MD Sanders 1995 310 1037 40 - 32.
Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. OphthalmologyBurnett A. J. Shortt S. G. Isaac-Renton J. King A. Werker D. Bowie W. R. 1998 105 1032 7 - 33.
Direct genotyping of Toxoplasma gondii in ocular fluid samples from 20 patients with ocular toxoplasmosis: predominance of type II in France. J Clin Microbiol.Fekkar A. Ajzenberg D. Bodaghi B. Touafek F. Le Hoang P. Delmas J. Robert P. Y. Dardé M. L. Mazier D. Paris L. 2011 49 1513 7 - 34.
18 325 333 Hori J, Vega JL, Masli S. Review of ocular immune privilege in the year 2010: modifying the immune privilege of the eye. Ocul Immunol Inflamm 2010;18: 325-333 - 35.
Streilein JW. Tissue barriers, immunosuppressive microenvironments, and privileged sites: the eye’s point of view. Reg Immunol1993 5 253 268 - 36.
Forrester JV. Privilege revisited: an evaluation of the eye’s defence mechanisms. Eye (Lond)2009 23 756 766 - 37.
Bora NS, Gobleman CL, Atkinson JP, Pepose JS and Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci1993 34 13 3579 3584 - 38.
Endogenous cortisol and TGF-beta in human aqueous humor contribute to ocular immune privilege by regulating dendritic cell function. J ImmunolDenniston A. K. Kottoor S. H. Khan I. Oswal K. Williams G. P. Abbott J. Wallace G. R. Salmon M. Rauz S. Murray P. I. Curnow S. J. 2011 186 305 311 - 39.
J,Caspi RR. A new look at immune privilege of the eye: dual role for the vision-related molecule retinoic acid. J ImmunolZhou R. Horai R. Mattapallil M. J. Caspi R. R. A. new look. at immune. privilege of. the eye. dual role. for the. vision-related molecule. retinoic acid. 2011 187 4170 4177 - 40.
Ferguson TA, Griffith TS. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response. Chem Immunol Allergy,2007 92 140 154 - 41.
Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis SciRoychoudhury J. Herndon J. M. Yin J. Apte R. S. Ferguson T. A. 2010 51 3560 3566 - 42.
Denkers EY, Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev1998 11 569 588 - 43.
Parasite ImmunolJones L. A. Alexander J. Roberts C. W. Ocular toxoplasmosis. in the. storm of. the eye. 2006 28 635 42 - 44.
Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect ImmunNagineni C. N. Pardhasaradhi K. Martins M. C. Detrick B. Hooks J. J. 1996 64 4188 96 - 45.
Exp Parasitol,Gazzinelli R. T. Brezin A. Li Q. Nussenblatt R. B. Chan C. C. Toxoplasma gondii. acquired ocular. toxoplasmosis in. the murine. model protective. role of. T. N. F-alpha N-gamma I. F. 1994 78 217 29 - 46.
Gaddi PJ, Yap GS. Cytokine regulation of immunopathology in toxoplasmosis. Immunol Cell Biol2007 85 155 9 - 47.
In vitro effect of TNF-alpha and IFN-gamma in retinal cell infection with Toxoplasma gondii. Invest Ophthalmol Vis Sci.Delair E. Creuzet C. Dupouy-Camet J. Roisin M. P. 2009 50 1754 60 - 48.
181 2018 22 Yamamoto JH, Vallochi AL, Silveira C, Filho JK, Nussenblatt RB, Cunha-Neto E, Gazzinelli RT, Belfort R Jr, Rizzo LV. Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens. J Infect Dis 2000; 181: 2018-22 - 49.
Analysis of immunoregulatory cytokines in ocular fluid samples from patients with uveitis. Invest Ophthalmol Vis SciOngkosuwito J. V. Feron E. J. CE van Doornik der Lelij. A. Hoyng C. B. La Heij E. C. Kijlstra A. 1998 39 2659 65 - 50.
Rheumatology (Oxford)Yoshimura T. Sonoda K. H. Ohguro N. Ohsugi Y. Ishibashi T. Cua D. J. Kobayashi T. Yoshida H. Yoshimura A. Involvement of. Th cells the effect. of-I anti. L. therapy in. autoimmune uveitis. 2009 48 347 54 - 51.
Cytokine profiles in toxoplasmic and viral uveitis. J Infect DisLahmar I. Abou-Bacar A. Abdelrahman T. Guinard M. Babba H. Ben Yahia. S. Kairallah M. Speeg-Schatz C. Bourcier T. Sauer A. Villard O. Pfaff A. W. Mousli M. Garweg J. G. Candolfi E. 2009 199 1239 49 - 52.
Immunopathology in ocular toxoplasmosis: facts and clues. Mem Inst Oswaldo CruzGarweg J. G. Candolfi E. 2009 104 211 20 - 53.
14 1845 9 Cordeiro CA, Moreira PR, Costa GC, Dutra WO, Campos WR, Oréfice F, Teixeira AL Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol Vis 2008; 14: 1845-9 - 54.
TNF-alpha gene polymorphism (-308G/A) and toxoplasmic retinochoroiditis. Br J OphthalmolCA Cordeiro Moreira. P. R. Costa G. C. Dutra W. O. Campos W. R. Oréfice F. Teixeira A. L. T. N. 2008 92 986 8 - 55.
49 1979 82 Cordeiro CA, Moreira PR, Andrade MS, Dutra WO, Campos WR, Oréfice F, Teixeira AL. Interleukin-10 gene polymorphism (-1082G/A) is associated with toxoplasmic retinochoroiditis. Invest Ophthalmol Vis Sci 2008; 49: 1979-82 - 56.
Mem Inst Oswaldo Cruz,Albuquerque M. C. Aleixo A. L. Benchimol E. I. Leandro A. C. das Neves. L. B. Vicente R. T. Bonecini-Almeida Mda. G. Amendoeira M. R. The I. F. N-gamma +8. gene T. A. polymorphism is. associated with. retinochoroiditis toxoplasmosis. susceptibility 2009 2009 104 451 5 - 57.
Clinical manifestations of ocular toxoplasmosis. Ocul Immunol InflammDelair E. Latkany P. Noble A. G. Rabiah P. Mc Leod R. Brezin A. P. 2011 19 91 102 - 58.
Clinical pattern of ocular toxoplasmosis treated in a referral centre in Serbia. Eye (Lond)Kovačević-Pavićević D. Radosavljević A. Ilić A. Kovačević I. Djurković-Djaković O. 2012 26 723 8 - 59.
Garweg JG, de Groot-Mijnes JD and Montoya JG. Diagnostic approach to ocular toxoplasmosis. Ocul Immunol Inflamm2011 19 255 261 - 60.
Usefulness of immunoblotting and Goldmann-Witmer coefficient for biological diagnosis of toxoplasmic retinochoroiditis. Eur J Clin Microbiol Infect DisRobert-Gangneux F. Binisti P. Antonetti D. Brezin A. Yera H. Dupouy-Camet J. 2004 23 34 38 - 61.
Analysis of aqueous humor in ocular toxoplasmosis. N Engl J MedBrezin A. P. CE Eqwuagu Silveira. C. Thulliez P. Martins M. C. Mahdi R. M. Belfort Jr R. Nussenblatt R. B. 1991 - 62.
Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmolde Boer J. H. Verhagen C. Bruinenberg M. Rothova A. de Jong P. T. Baarsma G. S. Van der Lelij A. Ooyman F. M. Bollemeijer J. G. Derhaag P. J. Kijlstra A. 1996 121 650 658 - 63.
Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J OphthalmolJD De Groot-Mijnes Rothova. A. Van Loon A. M. Schuller M. Ten Van Dam. Loon N. H. De Boer J. H. Schuurman R. Weersink A. J. 2006 141 313 318 - 64.
Am J OphthalmolFardeau C. Romand S. Rao N. A. Cassoux N. Bettembourg O. Thulliez P. Lehoang P. Diagnosis of. toxoplasmic retinochoroiditis. with atypical. clinical features. 2002 134 196 203 - 65.
46 1965 1967 Fekkar A, Bodaghi B, Touafek F, Le Hoang P, Mazier D, Paris L. Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol 2008; 46:1965-1967 - 66.
Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis. J Clin MicrobiolVillard O. Filisetti D. Roch-Deries F. Garweg J. Flament J. Candolfi E. 2003 41 3537 3541 - 67.
Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J OphthalmolWesteneng A. C. Rothova A. de Boer J. H. de Groot-Mijnes J. 2007 144 781 785 - 68.
47 2131 5 Talabani H, Asseraf M, Yera H, Delair E, Ancelle T, Thulliez P, Brézin AP, Dupouy-Camet J.Contributions of immunoblotting, real-time PCR, and the Goldmann-Witmer coefficient to diagnosis of atypical toxoplasmic retinochoroiditis. J Clin Microbiol 2009; 47: 2131-5 - 69.
Early aqueous humor analysis in patients with human ocular toxoplasmosis. J Clin MicrobiolGarweg J. G. Jacquier P. Boehnke M. 2000 - 70.
Aqueous humor and serum immunoblotting for immunoglobulin types G, A, M, and E in cases of human ocular toxoplasmosis. J Clin MicrobiolGarweg J. G. Garweg S. D. Flueckiger F. Jacquier P. Boehnke M. 2004 42 4593 4598 - 71.
Comparison between two amplification sets for molecular diagnosis of toxoplasmosis by real-time PCR. J. Clin. MicrobiolCassaing S. Bessieres M. H. Berry A. Berrebi A. Fabre R. Magnaval J. F. 2006 44 720 724 - 72.
M. van Loon A, de Groot-Mijnes JD. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. OphthalmologyRothova A. de Boer J. H. Ten Dam-van. Loon N. H. Postma G. de Visser L. Zuurveen . S. J. Schuller M. Weersink A. J. 2008 115 306 311 - 73.
Stanford MR, Gilbert RE. Treating ocular toxoplasmosis: current evidence. Mem Inst Oswaldo Cruz2009 104 312 315 - 74.
Therapy for ocular toxoplasmosis. Ocul Immunol Inflammde-la-Torre A. Stanford M. Curi A. Jaffe G. J. Gomez-Marin J. E. 2011 19 314 320 - 75.
Vance SK, Freund KB, Wenick AS, Nguyen QD, Holland GN and Kreiger AE. Diagnostic and therapeutic challenges. Retina2011 31 1224 1230 - 76.
Controversies in ocular toxoplasmosis. Ocul Immunol InflammWakefield D. Cunningham E. T. Jr Pavesio C. Garweg J. G. Zierhut M. 2011 19 2 9 - 77.
Am J OphthalmolBosch-Driessen L. H. Verbraak F. D. MS Suttorp-Schulten van Ruyven. R. L. Klok A. M. Hoyng C. B. Rothova A. A. prospective randomized. trial of. pyrimethamine vs azithromycin pyrimethamine. sulfadiazine for. the treatment. of ocular. toxoplasmosis 2002 134 1 34 40 - 78.
Trimethoprim/Sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. Ocul Immunol InflammYazici A. Ozdal P. C. Taskintuna I. Kavuncu S. Koklu G. Trimethoprim 2009 17 289 291 - 79.
Sense and nonsense of corticosteroid administration in the treatment of ocular toxoplasmosis. Br J OphthalmolBosch-Driessen L. H. Rothova A. 1998 82 8 858 860 - 80.
Short-term effects of the clindamycin-steroid regimen in the treatment of ocular toxoplasmosis. J Chemother.Djurkovic-Djakovic O. Stanojevic-Paovic A. Bobic B. Bergam J. Nikolic A. Paovic J. Vukovic D. 1995 Nov;7 Suppl4 199 201 - 81.
Mc Leod R. Kieffer F. Sautter M. Hosten T. Pelloux H. Why prevent. diagnose treat congenital. toxoplasmosis? Mem. Inst Oswaldo. Cruz 2009 104 320 44 - 82.
Treatment for congenital toxoplasmosis: finding out what works. Mem Inst Oswaldo CruzGilbert R. 2009 104 305 311 - 83.
Long-term ocular outcome in congenital toxoplasmosis: A prospective cohort of treated children. J InfectFaucher B. Garcia-Meric P. Franck J. Minodier P. Francois P. Gonnet S. L’Ollivier C. Piarroux R. 2012 64 104 109 - 84.
Prevention of retinochoroiditis in congenital toxoplasmosis: Europe versus South America. Pediatr Infect Dis J.Sauer A. de la Torre A. Gomez-Marin J. Bourcier T. Garweg J. Speeg-Schatz C. Candolfi E. 2011 30 601 3 - 85.
Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis JPeyron F. Garweg J. G. Wallon M. Descloux E. Rolland M. Barth J. 2011 30 597 600 - 86.
TherapieWallon M. Kieffer F. Binquet C. Thulliez P. Garcia-Méric P. Dureau P. Franck J. Peyron F. Bonnin A. Villena I. Bonithon-Kopp C. Gouyon J. B. Masson S. Félin A. Cornu C. Congenital toxoplasmosis. randomised comparison. of strategies. for retinochoroiditis. prevention 2011 66 473 80 French.